| pubmed-article:3826937 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3826937 | lifeskim:mentions | umls-concept:C0024299 | lld:lifeskim |
| pubmed-article:3826937 | lifeskim:mentions | umls-concept:C0231335 | lld:lifeskim |
| pubmed-article:3826937 | lifeskim:mentions | umls-concept:C0025677 | lld:lifeskim |
| pubmed-article:3826937 | lifeskim:mentions | umls-concept:C1135615 | lld:lifeskim |
| pubmed-article:3826937 | lifeskim:mentions | umls-concept:C0442711 | lld:lifeskim |
| pubmed-article:3826937 | lifeskim:mentions | umls-concept:C0205349 | lld:lifeskim |
| pubmed-article:3826937 | lifeskim:mentions | umls-concept:C1548161 | lld:lifeskim |
| pubmed-article:3826937 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:3826937 | pubmed:dateCreated | 1987-4-15 | lld:pubmed |
| pubmed-article:3826937 | pubmed:abstractText | From january 1982 to january 1986 we treated 23 pediatric patients who had non Hodgkin's lymphoma, with a new therapeutic protocol. This protocol is based on the LSA2 L2, modified during the induction phase with high-dose methotrexate and increasing of intrathecal therapy. Nineteen patients (83%) were in stages III and IV and the 47.4% were in stage IV. The distribution according to histology was: 10 Burkitt's undifferentiated lymphomas; 2 non-Burkitt's undifferentiated lymphomas; 5 lymphoblastic lymphomas convoluted-cells; 5 lymphoblastic lymphoma non-convoluted cells and 1 indeterminate lymphoma. The follow-up oscillated between 6 months and 4 years. The total survival rate is 82.6% with a 100% survival in stages I, II and III and 63.5% in stage IV. The survival according histology is 91.7% for undifferentiated lymphomas and 70% for lymphoblastic lymphomas; the actuarial survival rates in the two groups at 30 months are 87% and 55% respectively (p greater than 0.10). We concluded that adding high-dose methotrexate to the LSA2 L2 protocol improve the survival rate in undifferentiated lymphomas and in a less extent in lymphoblastic lymphomas, without significant toxicity. This new protocol is mainly indicated in undifferentiated and indeterminate non-Hodgkin's lymphomas. | lld:pubmed |
| pubmed-article:3826937 | pubmed:language | spa | lld:pubmed |
| pubmed-article:3826937 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3826937 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3826937 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3826937 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3826937 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3826937 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3826937 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3826937 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3826937 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:3826937 | pubmed:issn | 0302-4342 | lld:pubmed |
| pubmed-article:3826937 | pubmed:author | pubmed-author:Sánchez de... | lld:pubmed |
| pubmed-article:3826937 | pubmed:author | pubmed-author:Prats ViñasJJ | lld:pubmed |
| pubmed-article:3826937 | pubmed:author | pubmed-author:Pérez... | lld:pubmed |
| pubmed-article:3826937 | pubmed:author | pubmed-author:Macía MartíJJ | lld:pubmed |
| pubmed-article:3826937 | pubmed:author | pubmed-author:Gallego... | lld:pubmed |
| pubmed-article:3826937 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3826937 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:3826937 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3826937 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3826937 | pubmed:pagination | 15-21 | lld:pubmed |
| pubmed-article:3826937 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3826937 | pubmed:meshHeading | pubmed-meshheading:3826937-... | lld:pubmed |
| pubmed-article:3826937 | pubmed:meshHeading | pubmed-meshheading:3826937-... | lld:pubmed |
| pubmed-article:3826937 | pubmed:meshHeading | pubmed-meshheading:3826937-... | lld:pubmed |
| pubmed-article:3826937 | pubmed:meshHeading | pubmed-meshheading:3826937-... | lld:pubmed |
| pubmed-article:3826937 | pubmed:meshHeading | pubmed-meshheading:3826937-... | lld:pubmed |
| pubmed-article:3826937 | pubmed:meshHeading | pubmed-meshheading:3826937-... | lld:pubmed |
| pubmed-article:3826937 | pubmed:meshHeading | pubmed-meshheading:3826937-... | lld:pubmed |
| pubmed-article:3826937 | pubmed:meshHeading | pubmed-meshheading:3826937-... | lld:pubmed |
| pubmed-article:3826937 | pubmed:meshHeading | pubmed-meshheading:3826937-... | lld:pubmed |
| pubmed-article:3826937 | pubmed:meshHeading | pubmed-meshheading:3826937-... | lld:pubmed |
| pubmed-article:3826937 | pubmed:meshHeading | pubmed-meshheading:3826937-... | lld:pubmed |
| pubmed-article:3826937 | pubmed:meshHeading | pubmed-meshheading:3826937-... | lld:pubmed |
| pubmed-article:3826937 | pubmed:meshHeading | pubmed-meshheading:3826937-... | lld:pubmed |
| pubmed-article:3826937 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:3826937 | pubmed:articleTitle | [Non-Hodgkin? lymphoma in childhood, preliminary results of the LSA2 L2 protocol modified by high-dose methotrexate]. | lld:pubmed |
| pubmed-article:3826937 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3826937 | pubmed:publicationType | English Abstract | lld:pubmed |
